Adjuvant therapies after surgery for hepatocellular carcinoma with microvascular invasion / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 685-689, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-873817
ABSTRACT
The high recurrence rate of hepatocellular carcinoma (HCC) after surgery cannot be ignored, but there are still no consensus statements and guideline recommendations for adjuvant therapies after HCC surgery. Current studies have shown that microvascular invasion is one of the high-risk factors for postoperative recurrence of HCC, and for HCC patients with microvascular invasion, timely postoperative adjuvant therapy may delay the time to recurrence and bring benefits to patients. At this stage, the prevention of postoperative recurrence of HCC and the prolongation of survival time through adjuvant therapy have attracted more and more attention. This article reviews the research advances in adjuvant therapy after surgery for HCC with microvascular invasion in recent years, in order to provide reference and help for postoperative adjuvant therapies for HCC patients with microvascular invasion.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Guía de Práctica Clínica
/
Factores de riesgo
Idioma:
Chino
Revista:
Journal of Clinical Hepatology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS